肝癌患者PD-1、PD-L1、CMTM6水平与术后复发风险的相关性

被引：1

作者：

彭启旺

邓浩

刘小卫

机构：

[1] 武汉市红十字会医院普通外科

来源：

肝胆外科杂志 | 2023年 / 31卷 / 03期

关键词：

程序性死亡受体1; 肝癌; 程序性死亡配体; 趋化素样因子超家族6; 手术; 肿瘤复发;

D O I：

暂无

中图分类号：

R735.7 [肝肿瘤];

学科分类号：

100214 ;

摘要：

目的探讨肝癌患者程序性死亡受体1(PD-1)、程序性死亡配体(PD-L1)、趋化素样因子超家族6(CMTM6)水平与术后复发风险的相关性。方法前瞻性选取2017年6月～2018年6月我院肝癌术后患者102例，随访观察3年，采用Kaplan-Meier绘制复发曲线，并根据复发情况分为复发组和非复发组。收集两组一般资料、肿瘤因素、肝脏功能状态、健康状态及免疫水平(PD-1、PD-L1、CMTM6免疫组织化学染色情况),并采用Logistic回归分析影响肝癌患者术后复发的相关因素。结果随访结束，共3例因各种原因失访，最终纳入99例，Kaplan-Meier曲线累积复发率为35.35%,复发时间(25.80±3.20)月，其中复发组35例，非复发组64例；两组肿瘤直径、BCLC分期、PD-L1、PD-1、CMTM6对比差异具有统计学意义(P<0.05);多因素Logistic回归分析显示：PD-1(OR=3.632,95%CI1.393～9.470、CMTM6(OR=2.496,95%CI1.274～4.890)、肿瘤直径(OR=3.015,95%CI1.039～8.753)、PD-L1(OR=2.803,95%CI1.335～5.885)为肝癌术后复发的危险因素(均P<0.05)。结论 PD-1、PD-L1、CMTM6水平在肝癌术后复发过程中发挥着重要作用，这可能成为肝癌治疗的一个新方向。

引用

页码：209 / 213

页数：5

共 21 条

[1]

Survival Predictability Between the American Joint Committee on Cancer 8th Edition Staging System and the Barcelona Clinic Liver Cancer Classification in Patients with Hepatocellular Carcinoma..[J].Chen LiJu;Chang YunJau;Chang YaoJen.The oncologist.2020, 3

[2]

Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B ☆.[J].George V. Papatheodoridis;Vana Sypsa;George N. Dalekos;Cihan Yurdaydin;Florian Van Boemmel;Maria Buti;Jose Luis Calleja;Heng Chi;John Goulis;Spilios Manolakopoulos;Alessandro Loglio;Theodoros Voulgaris;Nikolaos Gatselis;Onur Keskin;Rhea Veelken;Marta Lopez-Gomez;Bettina E. Hansen;Savvoula Savvidou;Anastasia Kourikou;John Vlachogiannakos;Kostas Galanis;Ramazan I

[3]

Molecular and immune characteristics for lung adenocarcinoma patients with CMTM6 overexpression.[J].Hui Wang;Jinping Gao;Renfeng Zhang;Meng Li;Zhongmin Peng;Haiyong Wang.International Immunopharmacology.2020,

[4]

The role of myeloid-derived suppressor cells in increasing cancer stem-like cells and promoting PD-L1 expression in epithelial ovarian cancer..[J].Komura Naoko;Mabuchi Seiji;Shimura Kotaro;Yokoi Eriko;Kozasa Katsumi;Kuroda Hiromasa;Takahashi Ryoko;Sasano Tomoyuki;Kawano Mahiru;Matsumoto Yuri;Kodama Michiko;Hashimoto Kae;Sawada Kenjiro;Kimura Tadashi.Cancer immunology; immunotherapy : CII.2020, prepublish

[5]

Elucidation of the relationships of MET protein expression and gene copy number status with PD-L1 expression and the immune microenvironment in non-small cell lung cancer.[J].Katsuhiro Yoshimura;Yusuke Inoue;Kazuo Tsuchiya;Masato Karayama;Hidetaka Yamada;Yuji Iwashita;Akikazu Kawase;Masayuki Tanahashi;Hiroshi Ogawa;Naoki Inui;Kazuhito Funai;Kazuya Shinmura;Hiroshi Niwa;Takafumi Suda;Haruhiko Sugimura.Lung Cancer.2020,

[6] Targeting CMTM6 Suppresses Stem Cell-Like Properties and Enhances Antitumor Immunity in Head and Neck Squamous Cell Carcinoma [J].

Chen, Lei ;

Yang, Qi-Chao ;

Li, Yi-Cun ;

Yang, Lei-Lei ;

Liu, Jian-Feng ;

Li, Hao ;

Xiao, Yao ;

Bu, Lin-Lin ;

Zhang, Wen-Feng ;

Sun, Zhi-Jun .

CANCER IMMUNOLOGY RESEARCH, 2020, 8 (02) :179-191

[7]

Quantitative Assessment of CMTM6 in the Tumor Microenvironment and Association with Response to PD-1 Pathway Blockade in Advanced-Stage Non–Small Cell Lung Cancer.[J].Jon Zugazagoitia;Yuting Liu;Maria Toki;John McGuire;Fahad Shabbir Ahmed;Brian S. Henick;Richa Gupta;Scott N. Gettinger;Roy S. Herbst;Kurt A. Schalper;David L. Rimm.Journal of Thoracic Oncology.2019, 12

[8] The relationship between the PD-L1 expression of surgically resected and fine-needle aspiration specimens for patients with pancreatic cancer [J].